- Mainz Biomed NV MYNZ.OQ, MYNZ.O is expected to report resultson September 8 for the period ending March 31 2025 
- The Mainz Hessen-based company is expected to report revenue of $300 thousand, according to the estimate from one analyst, based on LSEG data. 
- LSEG's mean analyst estimate for Mainz Biomed NV is for a loss of $2.80 per share. 
- The one available analyst rating on the shares is "buy". 
- The mean earnings estimate of analysts was unchanged in the last three months.  
- Wall Street's median 12-month price target for Mainz Biomed NV is $14.00, about 88% above its last closing price of $1.68 
This summary was machine generated September 5 at 12:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)